Disclosure of Directors and Senior Managers Relevant Int

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer: AFT Pharmaceuticals Limited (AFT)
Date this disclosure made: 1-Sep-25
Date of last disclosure: 3-Jul-20
Director or senior manager giving disclosure
Full name(s): David Flacks
Name of listed issuer: AFT Pharmaceuticals Limited (AFT)
Name of related body corporate (if applicable): Not applicable
Position held in listed issuer: Director & Chair
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products: Fully-Paid Ordinary Shares in AFT
Nature of the affected relevant interest(s):
Joint registered holder and beneficial owner of ordinary
shares
For that relevant interest-
Number held in class before acquisition or disposal: 178,764
Number held in class after acquisition or disposal: 196,486
Current registered holder(s): N/A
Registered holder(s) once transfers are registered: David Mark Flacks & Adina Rita Betty Halpern as trustees
of Waitemata Family Trust
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 2
Details of transactions requiring disclosure-
Date of transaction: 28-Aug-25 & 29-Aug-25
Nature of transaction: On-market purchase of ordinary shares
Name of any other party or parties to the transaction (if known): Not applicable
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or
disposal. If the consideration was not in cash and cannot be readily by converted into a cash value,
describe the consideration: 17,722 shares at an average of $2.72 per share / $48,206
Number of financial products to which the transaction related: 17,722
If the issuer has a financial products trading policy that prohibits directors or senior managers from
trading during any period without written clearance (a closed period) include the following details—
Whether relevant interests were acquired or disposed of during a closed period: No
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during
the closed period: Not applicable
Date of the prior written clearance (if any): Not applicable
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products: Not applicable
Nature of relevant interest: Not applicable
For that relevant interest,-
Number held in class: Not applicable
Current registered holder(s): Not applicable
For a derivative relevant interest,-
Type of derivative: Not applicable
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial products
(if any): Not applicable
A statement as to whether the derivative is cash settled or physically settled: Not applicable
Maturity date of the derivative (if any): Not applicable
Expiry date of the derivative (if any): Not applicable
The price's specified terms (if any): Not applicable
Any other details needed to understand how the amount of the consideration payable under the
derivative or the value of the derivative is affected by the value of the underlying financial products:
Not applicable
For that derivative relevant interest,-
Parties to the derivative: Not applicable
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in
the derivative: Not applicable
Certification
I certify that, to the best of my knowledge and belief, the information contained in this disclosure is
correct and that I am duly authorised to make this disclosure by all persons for whom it is made.
Signature of director or officer:
Date of signature: 1-Sep-25

---

Announcement PDF